Robin Hamilton

University College London

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Sobha Sivaprasad

Moorfields Eye Hospital NHS Foundation Trust

Praveen J. Patel

University College London

Philip Hykin

University College London

Catherine Egan

University College London

Ranjan Rajendram

University College London

Dawn A. Sim

University College London

Faruque Ghanchi

Bradford Teaching Hospitals NHS Foundation Trust

Louise Downey

Hull and East Yorkshire Hospitals NHS Trust

Pearse A. Keane

National Institute for Health Research

Luke Nicholson

Moorfields Eye Hospital

Cooperative Institutions

University College London

241

Moorfields Eye Hospital

195

Moorfields Eye Hospital NHS Foundation Trust

187

National Institute for Health Research

National Health Service

Institute of Ophthalmology

NIHR Moorfields Biomedical Research Centre

University of Oxford

University of Iowa Hospitals and Clinics

King's College London

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Economic Assessment in Resource-Constrained Systems: Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema

Ophthalmology and Therapy (2024)

Danying Li Vladislav Berdunov Robin Hamilton Yaneth Gil Rojas C Bührer

Cost-effectiveness analyses typically ignore healthcare system resource constraints. Ophthalmology is affected by resource constraints because of increasing disease prevalence and the use of resource-intensive treatments. This study evaluated the impact of resource constraints on the cost-effectiveness of faricimab 6 mg, compared with aflibercept 2 mg and ranibizumab biosimilar 0.5 mg, for treating wet age-related macular degeneration (wAMD) or diabetic macular oedema (DMO) over a 5-year horizon.

Aflibercept

10.1007/s40123-024-00999-8

Cite

Citations (2)

Complete Resolution of a Giant Pigment Epithelial Detachment Secondary to Exudative Age-Related Macular Degeneration after a Single Intravitreal Ranibizumab (Lucentis) Injection: Results Documented by Optical Coherence Tomography

Case Reports in Ophthalmology (2010)

Eleni Loukianou Nacima Kisma Robin Hamilton

To describe a patient with a giant pigment epithelial detachment (PED) secondary to exudative age-related macular degeneration (ARMD) successfully treated with a single intravitreal ranibizumab (Lucentis) injection (0.5 mg/0.05 ml).An 89-year-old woman presented with a six-day history of reduced vision and distortion in the left eye. Best-corrected visual acuity in that eye was 6/15. Fundoscopy revealed a giant PED and exudates temporally to the fovea. Optical coherence tomography showed a PED associated with subretinal and intraretinal fluid. Fluorescein angiography confirmed the diagnosis of an occult choroidal neovascularization. Treatment with intravitreal injections of ranibizumab (Lucentis) was recommended, although the increased risk of retinal pigment epithelium (RPE) rip was mentioned.Four weeks after the first intravitreal Lucentis injection, the visual acuity in the left eye improved to 6/7.5, with a significant improvement of the distortion and a complete anatomical resolution of the PED confirmed by optical coherence tomography.Giant PED secondary to exudative ARMD can be successfully treated with intravitreal ranibizumab, despite the increased risk of RPE rip. To our knowledge, this is the first case presenting with complete resolution of PED after a single ranibizumab injection.

10.1159/000321730

Cite

Citations (2)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration

Eye (2020)

Shruti Chandra Cristina Arpa Deepthy Menon Hagar Khalid Robin Hamilton

10.1038/s41433-020-0764-9

Cite

Citations (68)

Eccentric Viewing Training for Age-Related Macular Disease

Ophthalmology Science (2023)

Gary S. Rubin Michael D. Crossland Hannah Dunbar G.M. Brown Bledi Petriti

Eccentric viewing training for macular disease has been performed for > 40 years, but no large studies including control groups have assessed the benefits of this training. The EFFECT (Eccentric Fixation From Enhanced Clinical Training) study is a large randomized controlled trial of 2 types of eccentric viewing training.

Eccentric training

Eccentric exercise

10.1016/j.xops.2023.100422

Cite

Citations (1)

Efficacy of Aflibercept in Treatment-naïve Neovascular Age-related Macular Degeneration: One-Year Real World Outcomes

Investigative Ophthalmology & Visual Science (2015)

Maria Eleftheriadou Clara Vázquez-Alfageme Maria Cristina Citu Roxanne Crosby‐Nwaobi Sobha Sivaprasad

Aflibercept

Source

Cite

Citations (0)

The evolving role of nurses and allied health professionals in the management of age-related macula degeneration

Acta Ophthalmologica (2015)

Robin Hamilton Adam Mapani Joanna DaCosta Carlos Pavésio D W Flanagan

One of the major developments within the medical retinal (MR) over the last five years has been the introduction of an intravitreal injection of anti-vascular endothelial growth factor medications (Anti-VEGFs) for patients with AMD and other macular disease. As a consequence of this development, outpatient attendances within the MR Service have increased significantly. The Royal College of Ophthalmologists acknowledges challenges related to staffing levels. A document produced by the Royal College of Ophthalmologists in 2009 stated that training nurses or technicians to perform intravitreal injections may offer a potential solution to increased pressure in the retinal therapies clinics despite the label recommending that intravitreal injections be given by trained ophthalmologists. Nursing staff at Moorfields Eye Hospital have given over 15,000 injections now and are currently giving over 60% of all injections. Enabling nurses to be trained to perform intravitreal injections has improved the efficient delivery and capacity of the injection service and enabled national guidelines and service delivery targets to be met, whilst maintaining high standards of care with an excellent safety record.

Staffing

10.1111/j.1755-3768.2015.0191

Cite

Citations (0)

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study

PLoS ONE (2020)

Frank G. Holz Angelo Maria Minnella Raman Tuli Pradeepa Yoganathan Soumil Parikh

Purpose To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS ™ study. Patients and methods LUMINOUS, a 5-year, prospective, multicenter, observational study, recruited 30,138 adult patients (treatment-naïve or prior ranibizumab-treated or other ocular treatments) across all approved indications for ranibizumab. Patients were treated as per local ranibizumab label of participating countries. Here we report the mean change in visual acuity (VA) at Year 1, treatment exposure, overall incidence of ocular, non-ocular adverse events (AEs) and serious AEs (SAEs) in prior ranibizumab-treated nAMD patients (n = 16,167). Results At baseline, the mean (standard deviation [SD]) age of patients was 78.4 (9.0) years, 59.0% were female, and 80.0% were Caucasian. At Year 1 (n = 10,168), the mean (SD) VA change was −1.6 (12.6) letters (baseline VA: 58.3 [19.0] letters) with a mean (SD) of 4.7 (3.1) ranibizumab injections. Stratified by duration of prior ranibizumab treatment of <1 (n = 4,112), 1 to <2 (n = 2,095), 2 to <3 (n = 1,506), 3 to <4 (n = 1,123), 4 to <5 (n = 689), and ≥5 (n = 256) years, the mean (SD) VA change at Year 1 were −1.2 (13.5), −2.0 (12.3), −2.0 (11.3), −1.9 (11.8), −2.5 (10.9), and 0.0 (11.2) letters, respectively. Mean (SD) VA change in patients who received ≤6 and >6 injections over 1 year was −1.8 (13.8) and +0.5 (12.5) letters, respectively. The rate of ocular/non-ocular AEs and SAEs across all prior ranibizumab-treated patients over 5 years were 13.29%/23.02% and 0.84%/13.66%, respectively. Conclusions Overall, regardless of the prior ranibizumab-treatment duration, VA was maintained in these patients at Year 1, and those receiving ≥6 injections showed a trend towards gaining letters. There were no new safety signals. These results may help inform routine clinical practice to appropriately treat nAMD patients with ranibizumab to achieve optimal visual outcomes.

10.1371/journal.pone.0244183

Cite

Citations (8)

Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group

Eye (2020)

Winfried M. K. Amoaku Faruque Ghanchi Clare Bailey Sanjiv Banerjee Somnath Banerjee

Grading (engineering)

10.1038/s41433-020-0961-6

Cite

Citations (156)

Contents

Deleted Journal (2022)

Sandeep Ravindran Noemi Lois Christina Campbell Norman Waugh Augusto Azuara‐Blanco

Subthreshold micropulse laser therapy was found to be equivalent to standard laser therapy for the treatment of central-involving diabetic macular edema of less than 400 mm in central retinal thickness.

10.1016/s0161-6420(22)00841-7

Cite

Citations (0)

Fluid Control in Neovascular Age-Related Macular Degeneration with Brolucizumab: An Analysis of the HAWK and HARRIER Phase 3 Trials

Ophthalmologica (2022)

Carl D. Regillo Rishi P. Singh Robin Hamilton Kinfemichael Gedif Catherine Best

Introduction: Neovascular age-related macular degeneration (nAMD) is characterized by exudation of fluid from abnormally growing blood vessels in the macula. Anti-vascular endothelial growth factor (VEGF) therapy is standard treatment for nAMD. Fluid resolution is used both as an indicator of disease control and to guide the frequency of treatment because of anti-VEGF therapy effectiveness in reducing neovascularization-related exudation. Herein reports a post hoc assessment of the HAWK and HARRIER trials comparing the efficacy and safety of brolucizumab with aflibercept in patients with nAMD. Materials and Methods: HAWK randomized 1,078 patients with untreated, active choroidal neovascularization due to AMD in the study eye to receive brolucizumab 3, 6 mg or aflibercept 2 mg. In HARRIER, 739 patients received brolucizumab 6 mg or aflibercept 2 mg. Brolucizumab was injected at weeks 0, 4, and 8, and thereafter q12w unless disease activity was identified (injection interval: q8w). Aflibercept was injected q8w after the loading phase, aligned with approved dosing at study initiation. The objective of this analysis was to assess effects of brolucizumab versus aflibercept on retinal fluid resolution during two phase 3 trials (HAWK and HARRIER) in patients with nAMD. Anatomical assessments for intraretinal fluid (IRF) and subretinal fluid (SRF) were performed every 4 weeks by spectral domain optical coherence tomography. Sustained dryness was defined as a patient being fluid-free (SRF and IRF) on ≥3 consecutive visits. Time to sustained dryness was determined by Kaplan-Meier estimates. Results: At week 96, fluid resolution (absence of IRF and SRF) was achieved by more brolucizumab- (6 mg; 76.1%) versus aflibercept-treated patients (63.1%; p = 0.0002, HAWK); 75.4% versus 61.8% (p < 0.0001, HARRIER). More patients achieved sustained dryness with brolucizumab versus aflibercept: at 96 weeks, 87.9% (brolucizumab 3 mg) and 86.1% (brolucizumab 6 mg) versus 82.0% (aflibercept) in HAWK, and 91.2% (brolucizumab) versus 78.0% (aflibercept) in HARRIER. Sustained dryness was achieved faster and hence with fewer brolucizumab injections. Discussion/Conclusion: Brolucizumab dried the macula in patients with nAMD faster and to a greater degree than aflibercept. Achieving sustained dryness faster, and therefore with fewer injections, provides an opportunity for earlier decisions relating to treatment interval extension potentially reducing treatment burden.

Aflibercept

10.1159/000524096

Cite

Citations (8)